Mantle Cell Lymphoma

>

Latest News

BOVen Regimen Appears Effective in High-Risk MCL
BOVen Regimen Appears Effective in High-Risk MCL

October 25th 2024

Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.

Acalabrutinib Receives FDA Priority Review in Frontline MCL
Acalabrutinib Receives FDA Priority Review in Frontline MCL

October 3rd 2024

FDA Approves Ready-to-Use Subcutaneous Bortezomib Formulation
FDA Approves Ready-to-Use Subcutaneous Bortezomib Formulation

September 6th 2024

Frontline Acalabrutinib/BR Regimen Improves PFS in MCL
Frontline Acalabrutinib/BR Regimen Improves PFS in MCL

August 13th 2024

New MCL Treatment Shows Promise for Older Patients: BOVen Regimen Well-Tolerated with High Response Rates
New MCL Treatment Shows Promise for Older Patients: BOVen Regimen Well-Tolerated with High Response Rates

July 8th 2024

Video Series
Video Interviews

More News